Adjuntive nicergoline therapy for severe persistent corneal epithelial defects.
Purpose: The aim of this study was to determine the effect of nicergoline in patients with persistent corneal epithelial defects. Methods: This is a prospective, non-comparative interventional study. The study included ten eyes of 9 patients with persistent corneal epithelial defects unresponsive to...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | AJO International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950253525000061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595720004173824 |
|---|---|
| author | Valeria Oliva-Biénzobas Enrique O. Graue-Hernandez Guillermo Raul Vera-Duarte Jesus Cabral-Macías Juan Serna-Ojeda Victor Boullosa Arturo Ramirez-Miranda Vishal Jhanji Victor L. Perez Alejandro Navas |
| author_facet | Valeria Oliva-Biénzobas Enrique O. Graue-Hernandez Guillermo Raul Vera-Duarte Jesus Cabral-Macías Juan Serna-Ojeda Victor Boullosa Arturo Ramirez-Miranda Vishal Jhanji Victor L. Perez Alejandro Navas |
| author_sort | Valeria Oliva-Biénzobas |
| collection | DOAJ |
| description | Purpose: The aim of this study was to determine the effect of nicergoline in patients with persistent corneal epithelial defects. Methods: This is a prospective, non-comparative interventional study. The study included ten eyes of 9 patients with persistent corneal epithelial defects unresponsive to conventional therapy. Patients were treated with 10 mg nicergoline orally twice daily for at least two weeks. Slit-lamp examination, photography, corneal fluorescein dye testing, and best-corrected visual acuity were performed before and after treatment. Results: Two male and seven female patients with persistent corneal epithelial defects unresponsive to conventional therapy treated with oral nicergoline were included. The average age was 60.9 years (51–76 years). The most frequent diagnoses associated with persistent corneal defects were neurotrophic (3 patients) and exposure ulcer (2 patients). In eight eyes (72.7 %), epithelial defects entirely healed between 10 and 28 days of treatment with nicergoline (mean resolution time 17 days). Epithelial defects persisted in 2 eyes (27.3 %). Conclusion: Nicergoline represents a potential therapeutic option in patients with abnormal corneal healing responses. Further studies and clinical trials must be conducted to prove safety and efficacy as a treatment for persistent corneal epithelium defects in humans. |
| format | Article |
| id | doaj-art-ea3e4247f18c4080924da9263a6a5125 |
| institution | Kabale University |
| issn | 2950-2535 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | AJO International |
| spelling | doaj-art-ea3e4247f18c4080924da9263a6a51252025-01-18T05:05:42ZengElsevierAJO International2950-25352025-04-0121100103Adjuntive nicergoline therapy for severe persistent corneal epithelial defects.Valeria Oliva-Biénzobas0Enrique O. Graue-Hernandez1Guillermo Raul Vera-Duarte2Jesus Cabral-Macías3Juan Serna-Ojeda4Victor Boullosa5Arturo Ramirez-Miranda6Vishal Jhanji7Victor L. Perez8Alejandro Navas9Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, MexicoUniversity of Pittsburgh, Department of OphthalmologyBascom Palmer Eye Institute, Department of OphthalmologyInstituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico; Correspondence author at: Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Chimalpopoca 14, Centro, Cuauhtémoc, 06800, Ciudad de México, CDMX. CP 06800 Mexico.Purpose: The aim of this study was to determine the effect of nicergoline in patients with persistent corneal epithelial defects. Methods: This is a prospective, non-comparative interventional study. The study included ten eyes of 9 patients with persistent corneal epithelial defects unresponsive to conventional therapy. Patients were treated with 10 mg nicergoline orally twice daily for at least two weeks. Slit-lamp examination, photography, corneal fluorescein dye testing, and best-corrected visual acuity were performed before and after treatment. Results: Two male and seven female patients with persistent corneal epithelial defects unresponsive to conventional therapy treated with oral nicergoline were included. The average age was 60.9 years (51–76 years). The most frequent diagnoses associated with persistent corneal defects were neurotrophic (3 patients) and exposure ulcer (2 patients). In eight eyes (72.7 %), epithelial defects entirely healed between 10 and 28 days of treatment with nicergoline (mean resolution time 17 days). Epithelial defects persisted in 2 eyes (27.3 %). Conclusion: Nicergoline represents a potential therapeutic option in patients with abnormal corneal healing responses. Further studies and clinical trials must be conducted to prove safety and efficacy as a treatment for persistent corneal epithelium defects in humans.http://www.sciencedirect.com/science/article/pii/S2950253525000061NicergolinePersistent epithelial defect (PED)Neurotrophic keratopathyTherapeutic |
| spellingShingle | Valeria Oliva-Biénzobas Enrique O. Graue-Hernandez Guillermo Raul Vera-Duarte Jesus Cabral-Macías Juan Serna-Ojeda Victor Boullosa Arturo Ramirez-Miranda Vishal Jhanji Victor L. Perez Alejandro Navas Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. AJO International Nicergoline Persistent epithelial defect (PED) Neurotrophic keratopathy Therapeutic |
| title | Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. |
| title_full | Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. |
| title_fullStr | Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. |
| title_full_unstemmed | Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. |
| title_short | Adjuntive nicergoline therapy for severe persistent corneal epithelial defects. |
| title_sort | adjuntive nicergoline therapy for severe persistent corneal epithelial defects |
| topic | Nicergoline Persistent epithelial defect (PED) Neurotrophic keratopathy Therapeutic |
| url | http://www.sciencedirect.com/science/article/pii/S2950253525000061 |
| work_keys_str_mv | AT valeriaolivabienzobas adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT enriqueograuehernandez adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT guillermoraulveraduarte adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT jesuscabralmacias adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT juansernaojeda adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT victorboullosa adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT arturoramirezmiranda adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT vishaljhanji adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT victorlperez adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects AT alejandronavas adjuntivenicergolinetherapyforseverepersistentcornealepithelialdefects |